Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 136 AL 150

[Profile of the informal carer associated with the clinical management of the Alzheimer's disease patient refractory to symptomatic treatment of the disease]

Molinuevo JL, Hernández B; Grupo de Trabajo del Estudio IMPACT.

Neurologia. 2011 Nov;26(9):518-27. doi: 10.1016/j.nrl.2011.05.011. Epub 2011 Jul 30.

Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before

Mancuso C, Siciliano R, Barone E, Butterfield DA, Preziosi P.

Expert Opin Investig Drugs. 2011 Sep;20(9):1243-61. doi: 10.1517/13543784.2011.601740. Epub 2011 Aug 2.

The radical scavenger IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate) decreases mortality, enhances cognitive functions in water maze and reduces amyloid plaque burden in hAβPP transgenic mice

Puoliväli J, Nurmi A, Miettinen TK, Soleti A, Riccardino F, Kalesnykas G, Heikkinen T, Vartiainen N, Pussinen R, Tähtivaara L, Lehtimäki K, Yrjänheikki J, Canistro D, Sapone A, Spisni E, Paolini M.

J Alzheimers Dis. 2011;27(3):499-510. doi: 10.3233/JAD-2011-110881.

Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II

Moriguchi S.

J Pharmacol Sci. 2011;117(1):6-11. doi: 10.1254/jphs.11r06cp. Epub 2011 Aug 6.

Berberine: a potential multipotent natural product to combat Alzheimer's disease

Ji HF, Shen L.

Molecules. 2011 Aug 9;16(8):6732-40. doi: 10.3390/molecules16086732.

Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease

Cho JE, Kim JR.

Recent Pat CNS Drug Discov. 2011 Sep 1;6(3):222-33. doi: 10.2174/157488911796958002.

New drugs for Alzheimer's disease in Japan

Takeda M, Tanaka T, Okochi M.

Psychiatry Clin Neurosci. 2011 Aug;65(5):399-404. doi: 10.1111/j.1440-1819.2011.02253.x.

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Karran E, Mercken M, De Strooper B.

Nat Rev Drug Discov. 2011 Aug 19;10(9):698-712. doi: 10.1038/nrd3505.

Alzheimer's disease: emerging trends in small molecule therapies

Mohamed T, Rao PP.

Curr Med Chem. 2011;18(28):4299-320. doi: 10.2174/092986711797200435.

Alzheimer's disease: clinical trials and the amyloid hypothesis

Cummings J.

Ann Acad Med Singap. 2011 Jul;40(7):304-6.

Role of serotonin in Alzheimer's disease: a new therapeutic target?

Geldenhuys WJ, Van der Schyf CJ.

CNS Drugs. 2011 Sep 1;25(9):765-81. doi: 10.2165/11590190-000000000-00000.

[Cytoskeletal alterations in Alzheimer's disease: the "skeleton" of therapeutic hope?]

Fodor KE, Pákáski M, Santha P, Janka Z, Kálmán J.

Neuropsychopharmacol Hung. 2011 Sep;13(3):163-71. doi: 10.5706/nph201109005.

[Pharmacological and clinical profiles of galantamine (Reminyl(®))]

Nagino K, Shikinami K, Saito T, Harada Y.

Nihon Yakurigaku Zasshi. 2011 Sep;138(3):122-6. doi: 10.1254/fpj.138.122.

Chronic divalproex sodium use and brain atrophy in Alzheimer disease

Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR Jr, Weiner MW, Thomas RG, Schneider LS, Tariot PN; Alzheimer's Disease Cooperative Study.

Neurology. 2011 Sep 27;77(13):1263-71. doi: 10.1212/WNL.0b013e318230a16c. Epub 2011 Sep 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias